Advancements in Vaccine Development : A comprehensive design of a Multi-Epitopic Immunodominant Peptide Vaccine Targeting Kyasanur Forest Disease via Reverse Vaccinology

Kyasanur Forest Disease (KFD), caused by the Kyasanur Forest Disease Virus (KFDV), is a tick-borne hemorrhagic fever virus first identified in Karnataka, South India, in 1957. The rising incidence of cases is alarming, particularly due to the potential spread of the disease to neighboring states. There presently exists no particular treatment, and the Chick embryo fibroblast (CEF) vaccine only provides temporary immunity and necessitates many doses, which results in poor immunisation rates among at-risk groups. This situation highlights the urgent need for a highly effective and user-friendly vaccine. Given that KFDV is classified as a BSL-4 pathogen, this study employs advanced immuno-informatics tools to design a safer vaccine construct. Promising results have identified the E protein of KFDV as an immunodominant target that can stimulate robust immune responses, including the production of neutralizing antibodies.

The vaccine design utilized various in silico tools to predict CTL, HTL and B-cell epitopes from the E protein, ensuring powerful immunological reactions. Quality attributes such as antigenicity, allergenicity, toxicity, and immunogenicity were assessed using specialized tools. A total of 16 epitopes (5 CTL, 3 HTL, and 8 B-cell) were identified, all exhibiting desirable properties like non-toxicity, non-allergenicity, high antigenic and immunogenic value. These epitopes were linked to form the PKFDVac-I vaccine, consisting of 279 amino acids with a MW of 29,162.32 Daltons. The constructed vaccine demonstrated stability and a robust immune response when docked with the TLR-4 receptor, indicating strong immunogenic potential. This multi-epitope peptide vaccine candidate developed via user-friendly and safer bio-informative tools represents a significant advancement in effective immunization strategies against KFDV infection, paving the way for future vaccine development efforts targeting other emerging infectious diseases. In conclusion, the integration of diverse epitopes into a cohesive vaccine prototype demonstrates a promising avenue for custom synthesis and application in immunization strategies. Further validation through in vitro and in vivo studies is essential to authorize the effectiveness of the designed vaccine construct.